Progynova Estrace Estradiol INDIA

Progynova Estrace contains estradiol, a synthetic form of the naturally occurring hormone estrogen. This hormone replacement therapy (HRT) is widely used to address conditions related to estrogen deficiency, such as menopausal symptoms, primary ovarian insufficiency, and prevention of osteoporosis in postmenopausal women. It is also sometimes prescribed as part of gender-affirming hormone therapy for transgender women.

Mécanisme d'action
Estradiol works by binding to estrogen receptors in target tissues, including the uterus, breasts, bones, and brain. This interaction promotes the regulation of physiological processes such as the menstrual cycle, lipid metabolism, bone density maintenance, and cardiovascular health. By supplementing endogenous estrogen levels, Progynova Estrace alleviates the effects of estrogen deficiency.

Indications

Progynova Estrace is commonly used to treat:

1. Menopausal Symptoms: Hot flashes, night sweats, mood swings, and vaginal atrophy.
2. Primary Ovarian Insufficiency: Conditions where the ovaries fail to produce sufficient estrogen.
3. Postmenopausal Osteoporosis: Reduces the risk of fractures by maintaining bone density.
4. Gender-Affirming Hormone Therapy: For transgender women as part of feminizing hormone regimens.

Dosage et administration

Progynova Estrace is available in oral tablet form. Dosage depends on the individual’s condition and therapeutic goals.

• Standard Dosage for Menopausal Symptoms: 1–2 mg daily.
• For Osteoporosis Prevention: 1 mg daily, adjusted based on response and bone density monitoring.
• In Gender-Affirming Therapy: Often combined with anti-androgens or progestogens; typical doses range from 2–6 mg daily, titrated based on clinical goals and serum estradiol levels.

Administration
Take the tablet orally with water, preferably at the same time each day. Consistency helps maintain stable hormone levels.

Effets secondaires

Common side effects include:

• Breast tenderness
• Nausées
• Maux de tête
• Weight changes

Serious but less common side effects include:

• Venous thromboembolism (VTE)
• Increased risk of breast or endometrial cancer
• Gallbladder disease

Précautions
Progynova Estrace is contraindicated in individuals with:

• A history of hormone-sensitive cancers
• Uncontrolled hypertension
• Active liver disease
• History of thromboembolic disorders

Réduction des risques

1. Medical Supervision: Always use under a doctor’s guidance with regular monitoring of blood pressure, liver function, and lipid profile.
2. Lifestyle Modifications: Incorporate a balanced diet, regular exercise, and smoking cessation to minimize risks.
3. Breast Cancer Screening: Annual mammograms are recommended.
4. VTE Risk Mitigation: Avoid prolonged immobility and discuss risks if undergoing surgery.

Progynova Estrace remains an essential therapy for addressing estrogen deficiency and associated conditions. By adhering to prescribed dosages and medical guidance, users can effectively manage symptoms while minimizing potential risks.ation that is used in the treatment of hormone receptor-positive breast cancer in postmenopausal women.